Literature DB >> 10051624

Immune surveillance against a solid tumor fails because of immunological ignorance.

A F Ochsenbein1, P Klenerman, U Karrer, B Ludewig, M Pericin, H Hengartner, R M Zinkernagel.   

Abstract

Many peripheral solid tumors such as sarcomas and carcinomas express tumor-specific antigens that can serve as targets for immune effector T cells. Nevertheless, overall immune surveillance against such tumors seems relatively inefficient. We studied immune surveillance against a s.c. sarcoma expressing a characterized viral tumor antigen. Surprisingly, the tumor cells were capable of inducing a protective cytotoxic T cell response if transferred as a single-cell suspension. However, if they were transplanted as small tumor pieces, tumors readily grew. Tumor growth correlated strictly with (i) failure of tumor cells to reach the draining lymph nodes and (ii) absence of primed cytotoxic T cells. Cytotoxic T cells were not tolerant or deleted because a tumor antigen-specific cytotoxic T cell response was readily induced in lymphoid tissue by immunization with virus or with tumor cells even in the presence of large tumors. Established tumors were rejected by vaccine-induced effector T cells if effector T cells were maintained by prolonged or repetitive vaccination, but not by single-dose vaccination. Thus, in addition to several other tumor-promoting parameters, some antigenic peripheral sarcomas-and probably carcinomas-may grow not because they anergize or tolerize tumor-specific T cells, but because such tumors are immunologically dealt with as if they were in a so-called immunologically privileged site and are ignored for too long.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051624      PMCID: PMC26766          DOI: 10.1073/pnas.96.5.2233

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Considerations of some current concepts in cancer research.

Authors:  G Möller; E Möller
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

2.  The homograft reaction.

Authors:  P B MEDAWAR
Journal:  Proc R Soc Lond B Biol Sci       Date:  1958-12-04

3.  A new analysis of allogeneic interactions.

Authors:  K J Lafferty; A J Cunningham
Journal:  Aust J Exp Biol Med Sci       Date:  1975-02

Review 4.  Cross-presentation: a general mechanism for CTL immunity and tolerance.

Authors:  F R Carbone; C Kurts; S R Bennett; J F Miller; W R Heath
Journal:  Immunol Today       Date:  1998-08

5.  Dendritic cells efficiently induce protective antiviral immunity.

Authors:  B Ludewig; S Ehl; U Karrer; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy.

Authors:  S Oehen; K Brduscha-Riem; A Oxenius; B Odermatt
Journal:  J Immunol Methods       Date:  1997-08-22       Impact factor: 2.303

Review 7.  Cancer vaccines.

Authors:  D M Pardoll
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

8.  Failure of immunosurveillance against chemically induced in situ tumors in mice.

Authors:  E J Andrews
Journal:  J Natl Cancer Inst       Date:  1974-03       Impact factor: 13.506

9.  A theory of self-nonself discrimination.

Authors:  P Bretscher; M Cohn
Journal:  Science       Date:  1970-09-11       Impact factor: 47.728

Review 10.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

View more
  95 in total

1.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs.

Authors:  Geetha Chalasani; Zhenhua Dai; Bogumila T Konieczny; Fady K Baddoura; Fadi G Lakkis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

Review 3.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

4.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 5.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

6.  Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Authors:  Vinod Singh; Qingyong Ji; Lionel Feigenbaum; Robert M Leighty; Arthur A Hurwitz
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

Review 7.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 8.  Mast cells as regulators of adaptive immunity to tumours.

Authors:  A Wasiuk; V C de Vries; K Hartmann; A Roers; R J Noelle
Journal:  Clin Exp Immunol       Date:  2008-12-05       Impact factor: 4.330

9.  Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

Authors:  Juan Fu; Ian-James Malm; Deepak K Kadayakkara; Hy Levitsky; Drew Pardoll; Young J Kim
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

Review 10.  Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.

Authors:  Malcolm K Brenner; Fatma V Okur
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.